Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.287
-0.023 (-7.39%)
Jan 27, 2025, 11:37 AM EST
Northwest Biotherapeutics Revenue
Northwest Biotherapeutics had revenue of $357.00K in the quarter ending September 30, 2024, a decrease of -12.07%. This brings the company's revenue in the last twelve months to $1.60M, down -23.42% year-over-year. In the year 2023, Northwest Biotherapeutics had annual revenue of $1.93M with 14.80% growth.
Revenue (ttm)
1.60M
Revenue Growth
-23.42%
P/S Ratio
232.51
Revenue / Employee
63.84K
Employees
25
Market Cap
410.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.93M | 249.00K | 14.80% |
Dec 31, 2022 | 1.68M | 678.00K | 67.46% |
Dec 31, 2021 | 1.01M | -286.00K | -22.15% |
Dec 31, 2020 | 1.29M | -1.12M | -46.43% |
Dec 31, 2019 | 2.41M | 2.00M | 484.95% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Silence Therapeutics | 21.77M |
SANUWAVE Health | 29.30M |
BioStem Technologies | 210.49M |
Northwest Biotherapeutics News
- 4 weeks ago - Northwest Biotherapeutics announces $5M convertible note financing and standby facility for up to $50M additional financing - Seeking Alpha
- 4 weeks ago - Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing - PRNewsWire
- 6 weeks ago - Northwest Biotherapeutics: All Is Not Well With This One - Seeking Alpha
- 7 months ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire
- 8 months ago - Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property - PRNewsWire
- 11 months ago - Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma - PRNewsWire